15. Process according to one of Claims 10 to 14, in which the aqueous or organic solution used in step E1 comprises, as binder, a hydrophilic polymer, preferably chosen from the group of cellulose derivatives (hydroxypropylcellulose or ethylcellulose), povidone (polyvinylpyrrolidone), sucrose, gums, starches, gelatin, macrogols (polyethylene glycols), which represent ~~approximately~~ from 15% to 45% and preferably 20% to 40% by weight of the said solution.

16. Process according to one of Claims 10 to 15, in which the aqueous or organic solution used in step E1 sprayed onto the fexofenadine is mixed with corn starch.

17. Process according to one of Claims 10 to 16, in which the weight percentage of the binder constituting ~~the coating of~~ the granule obtained in step E1 represents from 1% to 7% by weight relative to the weight of the composition for a hydrophilic polymer.

18. Process according to one of Claims 10 to 17, followed by a step E4 of formulation of the coated granules obtained in step E3 with excipients such as diluents, fillers, viscosity modifiers, disintegrants, dyes, sweeteners, salivating agents, flavourings, preserving agents, wetting agents, effervescent agents, lubricants, buffers and sequestrants for the manufacture of an oral formulation in the form of a composition of granules to be swallowed for sachets, granules for a drinkable suspension, granules for tablets or granules for orodispersible tablets.

19. Fexofenadine composition that may be obtained according to the process described in one of Claims 10 to 18.

20. Pharmaceutical composition comprising the fexofenadine composition as described in one of Claims 1 to 9 or as may be prepared according to the process as described in one of Claims 10 to 18.

21. Pharmaceutical ~~C~~composition according to Claim 20, ~~characterized in that it~~wherein said pharmaceutical composition is in the form of a sachet comprising a composition of granules to be swallowed or a sachet for a drinkable suspension and ~~characterized in that it contains~~further comprising one or more excipients, preferably chosen from diluents, viscosity modifiers, sequestrants, buffers, preserving agents, lubricants, wetting agents, effervescent agents, dyes, sweeteners, salivating agents and flavourings, and mixtures thereof.

22. Pharmaceutical ~~C~~composition according to Claim 20, ~~characterized in that it~~wherein said pharmaceutical composition is in the form of tablets, to be chewed, swallowed or sucked, or orodispersible tablets with masked taste,

and ~~characterized in that it contains~~further comprising one or more excipients, preferably chosen from diluents, binders, lubricants, salivating agents, anaesthetics, wetting agents, preserving agents, disintegrants, dyes, sweeteners, flavourings, and mixtures thereof.

23. Sachet or tablet according to Claim 21 or 22, ~~characterized in that~~wherein the weight ratio of the fexofenadine composition as defined according to one of Claims 1 to 9 relative to the weight amount of excipient in the sachet or tablet ranges from 0.2 to 0.8.

24. Use of a fexofenadine composition as defined in one of Claims 1 to 9 or prepared according to the process of any one of Claims 10 to 18, for the preparation of a pharmaceutical composition that is in the form of sachets comprising a composition of granules to be swallowed or for a drinkable suspension, tablets to be chewed, tablets to be swallowed, tablets to be sucked, or orodispersible tablets with masked taste.